| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 478.3 Million |
| Market Size in 2025 | USD 563.4 Million |
| Market Size by 2032 | USD 1878.5 Million |
| Projected CAGR | 18.8% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
|
Explore the market potential with our data-driven report
The cell dissociation market size was USD 478.3 million in 2024, and the market size is predicted to reach USD 1878.5 million by 2032, advancing at a CAGR of 18.8% during 2025–2032.
This is primarily ascribed to the growing awareness of stem cell research, the rising advancements in technology, and the surging need for personalized medicine and monoclonal antibodies. Moreover, the increasing prevalence of infectious and chronic diseases, the rising number of pharmaceutical and biotech companies, and growing government funding for the development of new drugs are contributing to the demand for cell dissociation.
For the development of vaccination for the prevention of multiple diseases, the study of single cells and the dissociation of a cluster of cellules is required. Hence, the vaccine preparation requires cells to be dissociated for in-detail study, which, in turn, boosts the development in the market. Moreover, some novel techniques have been introduced for dissociating living units of life from a sample, such as several microfluidic devices for dissociating digested tissues into single cells and magnetic-activated cellular sorting for separating the population of cellulite into sub-population.
The advancements in microfluidics technologies have made studies possible at the single-cell level, such as nanowell arrays, cell-trapping microfluidic devices, and droplet microfluidic devices. These devices are known to have the capability to perform various biological reactions by trapping a single cell. Due to the increase in the accuracy of results and recent advancements, the demand has increased for single-cell analysis, which, in turn, boosts the cell dissociation demand. The various approved cellular products and cellulite for performing cell-based therapy (CBT) applications are used for different (stem) therapies and treatments of a broad variety of diseases. Thus, these factors drive the market growth.
The enzymatic dissociation products category held the larger market share, of 50%, in 2024. This is attributed to its greater efficiency, gentle nature, and widespread use in veterinary medicine, biotechnological processes, and tissue culture lab.
The injection of collagenase has been approved by the FDA for the treatment of cellulite in adult women. Because of its availability in the form of injection, the market is expanding in this category. Also, collagenase and hyaluronidase are successfully used as isolation enzymes in treating breast cancer. Further, with the rising prevalence of glaucoma, the use of collagenase is also increasing. For instance, in 2022, according to government reports, more than 80 million people suffered from glaucoma and more than 3 million cases were reported only in the U.S.
In addition, the trypsin category is expected to show significant growth during the forecast period. This can be attributed to various reasons such as it is used to treat digestive disorders and helps in protein digestion.
The non-enzymatic dissociation products category will grow at the highest CAGR during the forecast period, this can be ascribed to the rising demand for non-enzymatic products because of their various advantages, such as non-toxic nature, ready-to-use, and high yield of viable cells during the dissociation process. It also reduces the risk of cellular damage, its components are derived from animals, and has gentle cellular disaggregation. Furthermore, the instruments and accessories category is expected to show significant growth in the future. This can be due to their efficiency and speed of tissue dissociation at the point of care and controlled shear forces.
The products analyzed here are:
The connective tissue category held the larger market share, of 60%, in 2024. This is because of the rising prevalence of cancer, which will rise the single cell-based research. For instance, in 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide, according to the International Agency for Research on Cancer (IARC). Moreover, it is composed of extracellular fibers and cells and the main component is collagen. The collagenase enzyme is used during the isolation of endothelial, epithelial, or adrenal tissue, and it is also used in the isolation of several cellulite types such as hepatocytes, adipocytes, and cardiomyocytes, and for the treatment of mammary or other soft tissues.
The tissues analyzed here are:
The pharmaceutical and biotech companies category held the larger market share, of 75%, in 2024, because of their rising R&D investments in various therapeutic areas for the introduction of novel drugs. Moreover, investments have also increased in various research activities including efficacy studies, clinical trials, and toxicity studies. These drive the need for dissociation products for the isolation of cells from primary tissues in pharmaceutical and biotechnology organizations.
Over the last few years, opportunities in the biopharmaceuticals sector have been increasing, as a result of the safety and great effectiveness of these drugs. Along with this, they provide several benefits, such as potent action and high effectiveness, have the potential to cure diseases rather than merely treat symptoms, and have fewer side effects, which have contributed to the growing demand for biopharmaceutical products. In addition, the increased spending in R&D activities by biopharmaceutical firms is further propelling the market in this category.
The end users analyzed here are:
Drive strategic growth with comprehensive market analysis
The North America held the largest market share, of 40%, in 2024. This is attributed to the surging cases of cancer and glaucoma and the increasing need for biopharmaceutical products. This can be attributed to the high focus on R&D related to biotechnology. Moreover, according to the American Cancer Society (ACS), approximately 2,001,140 new cancer cases and 611,720 cancer-related deaths were expected in the U.S. in 2024. In the U.S., the major cause of cancer is cigarette smoking. Smoking prevalence is higher among Alaskan and American women than men, and about a quarter of people suffering from cancer are regular cigarette smokers. Due to a large number of cancer cases, it became important to study the physiology and anatomy of a single cell. For converting tissue clusters into single cells, dissociation is required because it helps in recovering fully functional units of life with several methods.
The APAC region will grow at the highest CAGR, of 19%, during the forecast period. This is because biomedical and biotechnological research activity in China, India, South Korea, and Japan is rapidly expanding. This is fueled by massive investments by the governments and strategic national efforts to build national capabilities in the domain of life sciences. As these countries come to care more about innovation in healthcare, the number of research institutions, biotech startups, and clinical research activities will rise. This will, in turn, propel the demand for advanced tools for cellular analysis and processing, cell dissociation reagents, and instruments. In 2022, the World Health Organization's South-East Asia Region reported 2.4 million new cancer cases and 1.5 million cancer-related deaths.
The regions and countries analyzed in this report are:
The cell dissociation market is fragmented in nature because it includes a wide range of companies, from large global players to smaller regional and niche vendors. The major biopharmaceutical companies are focusing on the expansion of R&D in different therapeutic areas, in order to bring new pharmaceutical products. These players have initiated to invest significantly in toxicity studies, clinical trials, and efficacy studies, among others. In order to isolate cells from primary tissues, the majority of the research utilizes dissociation products. For instance, the U.S. Food and Drug Administration (FDA) approved 50 New Molecular Entities (NMEs) in 2024.
Additionally, biopharmaceutical companies are also focusing on the advancement of personalized medicine. Also, scientists and researchers are examining novel substances, so as to provide insights into the best medication targets and illuminate illness pathways. Therefore, it is expected that the market is fueled by the increasing R&D activities in the coming years.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages